NASDAQ · ASBP
Healthcare · Biotechnology
$7.97
Down-$0.03 (-0.31%)
Updated Aug 24, 2026, 6:50 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ASBP closed at $7.97 after 20 trading sessions, up 14.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $8.01 | $8.20 | $7.9023 | $7.97 | 31.92K |
| Aug 20, 2026 | $7.99 | $8.1532 | $7.77 | $7.82 | 15.98K |
| Aug 19, 2026 | $7.96 | $8.18 | $7.6176 | $7.90 | 44.67K |
| Aug 18, 2026 | $7.70 | $7.99 | $7.5046 | $7.64 | 12.09K |
| Aug 17, 2026 | $7.60 | $8.00 | $7.53 | $7.74 | 21.55K |
| Aug 14, 2026 | $7.15 | $7.90 | $7.14 | $7.85 | 34.76K |
| Aug 13, 2026 | $7.26 | $7.35 | $7.06 | $7.11 | 10.26K |
| Aug 12, 2026 | $7.74 | $7.81 | $7.09 | $7.13 | 26.94K |
| Aug 11, 2026 | $7.47 | $8.00 | $7.47 | $7.61 | 18.47K |
| Aug 10, 2026 | $7.92 | $8.00 | $7.33 | $7.79 | 83.47K |
| Aug 7, 2026 | $7.64 | $8.05 | $7.59 | $7.73 | 39.06K |
| Aug 6, 2026 | $7.42 | $7.89 | $7.06 | $7.06 | 39.22K |
| Aug 5, 2026 | $7.23 | $7.43 | $6.8931 | $7.26 | 10.23K |
| Aug 4, 2026 | $7.18 | $7.41 | $6.82 | $7.04 | 29.59K |
| Aug 3, 2026 | $6.72 | $7.44 | $6.71 | $7.23 | 27.44K |
| Jul 31, 2026 | $6.51 | $6.70 | $6.36 | $6.52 | 9.53K |
| Jul 30, 2026 | $5.94 | $6.72 | $5.94 | $6.72 | 14.24K |
| Jul 29, 2026 | $7.07 | $7.2399 | $4.87 | $5.61 | 119.76K |
| Jul 28, 2026 | $6.92 | $7.37 | $6.92 | $7.245 | 11.3K |
| Jul 27, 2026 | $7.15 | $7.50 | $6.71 | $6.97 | 29.66K |
The latest Smart Investors Daily articles mentioning ASBP.
ASBP research
Company profile and research snapshot.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Mar 3, 2026
Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset formulation planned for mid-2026. Alprazolam remains a top ...
Benzinga · Mar 3, 2026
Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted, patent-pending drug delivery technology, today announced a strategic partnership with
Benzinga · Feb 20, 2026
Benzinga · Feb 12, 2026
Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the filing of a provisional patent
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ASBP.
